National Institute of Tumours
National Institute of Tumours
Caraglia M.,National Institute of Tumours |
Santini D.,Biomedical University of Rome |
Bronte G.,University of Palermo |
Rizzo S.,University of Palermo |
And 4 more authors.
Current Drug Metabolism | Year: 2011
The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-related pathways are described, most relevant clinical findings about target therapy applications are exposed and the clinical impact of predictive factors of efficacy and toxicity are discussed.
Grieco P.,University of Naples Federico II |
Franco R.,National Institute of Tumours |
Bozzuto G.,Italian Institute of Technology |
Toccacieli L.,Italian Institute of Technology |
And 14 more authors.
Journal of Cellular Biochemistry | Year: 2011
Urotensin II (UT-II) is a potent vasoconstrictor peptide and its receptor (UTR) was correlated with human cortico-Adrenal carcinoma proliferation. In this study, we have evaluated the correlation between UTR expression and prognosis of human prostate adenocarcinoma and the involvement of this receptor in the regulation of biological properties on both in vivo and in vitro models. UTR mRNA and protein, evaluated by real-time PCR and Western blotting, respectively, were expressed at high levels only in androgen-dependent LNCaP cells. In order to investigate UTR changes occurring in human prostate tumorigenesis, we have also evaluated the expression of UTR in vivo in 195 human prostate tissue samples. UTR was always expressed at low intensity in hyperplastic tissues and at high intensity in well-differentiated carcinomas (Gleason 2-3). Moreover, we have evaluated the effects of an antagonist of UTR, urantide on migration and invasion of LNCaP cells. Urantide induced a dose-dependent decrease of motility and invasion of LNCaP cells whose characteristic ameboid movement seems to be advantageous for their malignancy. These effects were paralleled by down-regulating the autophosphorylation of focal adhesion kinase and the integrin surface expression on LNCaP cells. The effects on cell motility and invasion were likely due to the inhibition of RhoA activity induced by both urantide and shRNA UTR. These data suggest that UTR can be considered a prognostic marker in human prostate adenocarcinoma patients. J. Cell. Biochem. 112: 341-353, 2011. © 2010 Wiley Periodicals, Inc.
Battaglia L.,National Institute of Tumours |
Muscara C.,National Institute of Tumours |
Rampa M.,National Institute of Tumours |
Gasparini P.,National Institute of Tumours |
Vannelli A.,National Institute of Tumours
Giornale di Chirurgia | Year: 2012
A perineal hernia is defined as a protrusion of peritoneal or extraperitoneal content through a pelvic floor defect. A 64-year-old woman with a bowel occlusions due to a giant postoperative perineal hernia was admitted to our hospital. We describe abdominal approach with plastic perineal reconstruction. © 2012, CIC Edizioni Internazionali, Roma.
PubMed | National Institute of Tumours
Type: Journal Article | Journal: Il Giornale di chirurgia | Year: 2012
A perineal hernia is defined as a protrusion of peritoneal or extraperitoneal content through a pelvic floor defect. A 64-year-old woman with a bowel occlusions due to a giant postoperative perineal hernia was admitted to our hospital. We describe abdominal approach with plastic perineal reconstruction.